亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

A composition and related anti-viral uses thereof

總結: our formulation is on the market with the trademark NOVIR. Trademark is registered on my name, Erdal Can Alkoclar as the 16 patents which currently protects our intellectual property rights. This product is an effective anti-viral treatment specially formulated for influenza but may possess required properties sufficient to become a candidate as an adjunctive treatment for AiDS and viral origined cancers. About 450-500 million people worldwide suffers from flu and other viral ailments.NOVIR has the simultenaous ability to suppress DNA polymerase, ribonucleotide reductase and reverse transcriptase via rapid and simultenaous upregulation of tissue spesific cAMP and cGMP expression which leads to the potent suppression of above mentioned viral enzmyes. At the same time NOVIR has the ability to suppress pro-inflammatory cytokines such as TNF-A, cox-2, pge-2 and nf-kappaB expressions thus providing a double route treatment for both the cause and symptoms of viral infections.

附加資料: Patent Number: US8710248B2
Application Number: US13416657A
Inventor: Chan, Tak-Hang | Lam, Wai-Har | Chow, Larry Ming-Cheung | Dou, Qing Ping | Kuhn, Deborah Joyce | Kazi, Aslamuzzaman | Wan, Sheng Biao | Landis-Piwowar, Kristin R.
Priority Date: 19 Aug 2004
Priority Number: US8710248B2
Application Date: 9 Mar 2012
Publication Date: 29 Apr 2014
IPC Current: C07D031100 | A61K003125
US Class: 549399 | 514456
Assignee Applicant: The Hong Kong Polytechnic University
Title: (−)-epigallocatechin gallate derivatives for inhibiting proteasome | (−)-epigallocatechin gallate derivatives for inhibiting proteasome
Usefulness: (−)-epigallocatechin gallate derivatives for inhibiting proteasome | (−)-epigallocatechin gallate derivatives for inhibiting proteasome
Summary: Compounds (I) are used as medicaments to reduce tumor cell growth (claimed). Treated breast cancer (MCF-7) cells were treated with compounds (I) for 24 hours, followed by MTT analysis to determine their effects on cell proliferation. Compound (2S,3R)-trans-5,7-bis(acetyloxy)-2-[3,4,5-tris(acetyloxy)phenyl]chroman-3-yl-3-(acetyloxy)benzoate caused 70% inhibition at 25 μM.
Novelty: New chromanyl ester derivatives, are proteasome inhibitors used to reduce tumor cell growth

欲了解更多信息，請點擊這裡